BiCNU

BiCNU Patient Counseling Information

carmustine

Manufacturer:

Emcure

Distributor:

Advagen
Full Prescribing Info
Patient Counseling Information
Myelosuppression [see Precautions]: A serious and frequent toxicity of BiCNU is delayed myelosuppression and usually occurs 4 to 6 weeks after drug administration. Hence, patients should be advised to get blood counts monitored weekly for at least 6 weeks. The bone marrow toxicity of BiCNU is cumulative.
Pulmonary Toxicity [see Precautions]: Advise patients to contact a health care professional immediately for any of the following: shortness of breath, particularly during exercise, dry, hacking cough, fast, shallow breathing, gradual unintended weight loss, tiredness, aching joints and muscles, clubbing (widening and rounding) of the tips of the fingers or toes.
Seizures [see Adverse Reactions]: Inform the patient that they may suffer from fits and advise them to get medical attention immediately in such cases.
Pregnancy [see Precautions and Use in Pregnancy & Lactation]: Advise pregnant women and females of reproductive potential that BiCNU exposure during pregnancy can result in fetal harm. Advise female patients to contact their healthcare provider with a known or suspected pregnancy. Advise women of reproductive potential to avoid becoming pregnant. Advise females of reproductive potential to use effective contraception during treatment.
Lactation [see Precautions]: Advise the female patient to discontinue nursing while taking BiCNU.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in